Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBT440 DDI Study in Healthy Subjects
NCT02567682Phase 1Completed
- Sponsor
- Global Blood Therapeutics
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Global Blood Therapeutics. Primary endpoints: Peak plasma concentration for caffeine, S-warfarin, omeprazole, and midazolam, Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration for caffeine, S-warfarin, omeprazole, and midazolam and 1 more. Started Sep 2015; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02567682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567682.